Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Regenxbio (RGNX) reported a Q4 loss of $1.01 per share, which was better than the Zacks Consensus Estimate of a $1.27 loss. However, the company lagged in revenue estimates.
March 13, 2025 | 10:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regenxbio reported a Q4 loss of $1.01 per share, better than expected but missed revenue estimates. This mixed result may lead to short-term stock price volatility.
Regenxbio's Q4 loss was less than expected, which is positive, but missing revenue estimates is a negative. The mixed results could lead to uncertainty and volatility in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100